TIANJIN DEV (00882) announced its annual performance, with a net profit attributable to shareholders of HK$428 million, a decrease of 21.92% year-on-year.

Tianjin DEV (00882) announced its annual performance for the year ending December 31, 2025. The group achieved a revenue of HK$3.196 billion, a decrease of 4.86% year-on-year. The group's attributable net profit was HK$428 million, a decrease of 21.92% year-on-year. Basic earnings per share were 39.89 HK cents. The proposed final dividend is 8.82 HK cents per share. The announcement stated that in 2025, the revenue from the pharmaceutical segment was approximately HK$1.665 billion, representing a 3.4% increase from the previous year's HK$1.61 billion. Within this segment, revenue from the production and sale of chemical medicines, traditional Chinese medicines, and other health products was approximately HK$1.509 billion, a 3.7% increase from last year's HK$1.455 billion. Revenue from the sale of packaging materials was approximately HK$156 million, a 0.9% increase from HK$155 million in 2024.